Lunec J - Search Results

1

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: lunec j. Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523. Oncotarget. 2024. PMID: 38386812 Free PMC article. No abstract available.

2

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE. Bell HL, et al. Among authors: lunec j. Cancer Cell Int. 2023 Sep 15;23(1):202. doi: 10.1186/s12935-023-03057-8. Cancer Cell Int. 2023. PMID: 37715172 Free PMC article.

3

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Fernández AP, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Ladds MJGW, et al. Among authors: lunec j. Nat Commun. 2023 Aug 18;14(1):5019. doi: 10.1038/s41467-023-40764-2. Nat Commun. 2023. PMID: 37596290 Free PMC article. No abstract available.

4

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia.

Aptullahoglu E, Nakjang S, Wallis JP, Marr H, Marshall S, Willmore E, Lunec J. Aptullahoglu E, et al. Among authors: lunec j. Biomedicines. 2024 Jun 22;12(7):1388. doi: 10.3390/biomedicines12071388. Biomedicines. 2024. PMID: 39061962 Free PMC article.

5

Combination p53 activation and BCL-x_L/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE. Bell HL, et al. Among authors: lunec j. Leukemia. 2024 Jun;38(6):1223-1235. doi: 10.1038/s41375-024-02241-7. Epub 2024 Apr 10. Leukemia. 2024. PMID: 38600316 Free PMC article.

6

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.

Aptullahoglu E, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J. Aptullahoglu E, et al. Among authors: lunec j. Int J Mol Sci. 2023 Jul 12;24(14):11335. doi: 10.3390/ijms241411335. Int J Mol Sci. 2023. PMID: 37511096 Free PMC article.

7

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.

Aptullahoglu E, Ciardullo C, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J. Aptullahoglu E, et al. Among authors: lunec j. Int J Mol Sci. 2023 Jan 26;24(3):2410. doi: 10.3390/ijms24032410. Int J Mol Sci. 2023. PMID: 36768733 Free PMC article.

8

Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation.

Zadran B, Sudhindar PD, Wainwright D, Bury Y, Luli S, Howarth R, McCain MV, Watson R, Huet H, Palinkas F, Berlinguer-Palmini R, Casement J, Mann DA, Oakley F, Lunec J, Reeves H, Faulkner GJ, Shukla R. Zadran B, et al. Among authors: lunec j. Br J Cancer. 2023 Mar;128(7):1236-1248. doi: 10.1038/s41416-023-02154-9. Epub 2023 Jan 27. Br J Cancer. 2023. PMID: 36707636 Free PMC article.

9

In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.

Wu CE, Chen CP, Pan YR, Jung SM, Chang JW, Chen JS, Yeh CN, Lunec J. Wu CE, et al. Among authors: lunec j. Am J Cancer Res. 2022 Sep 15;12(9):4399-4410. eCollection 2022. Am J Cancer Res. 2022. PMID: 36225643 Free PMC article.

10

p53 as a biomarker and potential target in gastrointestinal stromal tumors.

Wu CE, Chen CP, Huang WK, Pan YR, Aptullahoglu E, Yeh CN, Lunec J. Wu CE, et al. Among authors: lunec j. Front Oncol. 2022 Jul 29;12:872202. doi: 10.3389/fonc.2022.872202. eCollection 2022. Front Oncol. 2022. PMID: 35965531 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters